Stages:
Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
Dr. rer. nat. / PhD
(2002 - 2006)
Diploma
(1997 - 2002)
2018
2018
2024
Glox Therapeutics is developing precision, engineered protein bacteriocins to target drug-resistant pathogenic bacteria.
2021
2021
Brainomix, Ltd. focuses on imaging software for neurological and cerebrovascular diseases and developed a software tool (e-ASPECTS) for the automated analysis of CT scans to detect early ischemic changes in the brain of patients with clinical signs of stroke. Currently, Brainomix utilizes its platform technology to expand into new therapeutic indications, including lung fibrosis and cancer. Brainomix is a spin-out from the University of Oxford, UK.
2020
2020
Perfood develops digital therapeutics powered by proprietary technology for personalized stable-glycemic nutrition. Perfood is building a pipeline of therapeutic solutions, where its core competence of modulating the glucose metabolism and inflammatory processes add disease-specific value. Find out more on www.perfood.de
2019
2019
Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. The goal is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Find out more on www.dopavision.com
2008 - 2018
2014 - 2018
2013 - 2014
2012 - 2013
2008 - 2011
2007 - 2008
2007 - 2008
2006 - 2007
2006 - 2007